Heart Rhythm Society (“HRS”) 2019
Permanent Pacing is Associated with Significant Decline in Blood Pressure among Elderly Patients with Drug Resistant Hypertension: A New Paradigm in Pacing?
Heart Rhythm Society (“HRS”) 2021
Permanent Atrial Pacing In Patients With Heart Failure And Preserved Lv Ejection Fraction: A Retrospective Analysis Of Clinical Outcomes.
American College of Cardiology (“ACC”) 2022
Beta Blocker Therapy Blunts the Blood Pressure Lowering Effect of Atrial Pacing in Hypertensive Patients: A Possible Confirmation of the Sympatholytic Effect of Pacing.
BaroPace, Inc. Announced First Patient Enrolled in Non-Pharmacologic Hypertension and Heart Failure Treatment Trial
August 22, 2023
BaroPace Inc announces first enrollment in its First-in-Human multi-center clinical trial in India, RelieveHFpEF-II.
May 9, 2022
BaroPace issued a Press Release announcing Michael Coyle has joined the Company’s Board.
AI Modeling to complete a fully autonomous PressurePace™ algorithm and closed loop system (Blood Pressure Measuring Device – PressurePace™ – Pacemaker) suitable for both the resting and exercise states including safety protocols, necessary encryption, and a device-specific homeware link for outpatient monitoring.
Completed: Acute Animal Model of Hypertension
November 17, 2021
PressurePace™ v2 with safety and security subroutines is successfully tested in an acute animal model of hypertension.
Scientific Advisory Board:
Three New Members
Mark Kroll PhD, Elisabeth Neely BA, BS, and Domenic Sica MD join the Company’s Scientific Advisory Board.
PressurePace™ Autonomous Bedside Module development begins.
The Module wirelessly receives blood pressure data, calculatesRead More
Further development of PressurePace™
PressurePace™ v2 will include more advanced treatment subroutines and the addition of system safeguards in preparation for human study. The design and modeling of PressurePace™ will begin.
Two multi-center prospective clinical trials receive IRB Approval: Chairside I, v3 and Treadmill I.
Chairside-I, v3 will study patients with DRH at rest to further develop PressurePace™. Treadmill I will study exercise performance and blood pressure control in patients with HFpEF using a PressurePace™ simulation.
First BaroPace™ Chairside Study is completed.
BaroPace™ successfully completed Chairside I, v1 Study. This clinical trial demonstrated the feasibility of significantly reducing both systolic and diastolic blood pressure in patients with hypertension and dual chamber pacemakers using PressurePace™. Trial results will be submitted for peer-reviewed publication.
Sapienza Medical School, Rome, Retrospective Study is completed and submitted for publication.
176 patients with DRH, HFpEF, and dual chamber pacemakers showed a significant drop in blood pressure and improvement in HFpEF.
PressurePace™ Engineering Prototype is completed.
Phase IIIA: Human Studies
BaroPace™ receives approval from the Institutional Review Board (IRB) to proceed with the Company’s first prospective multi-site clinical trial, the Chairside I, v1 Study.
Scientific Advisory Board: New Member
Uri Elkayam, MD, a nationally and internationally known expert in heart failure, joins the Scientific Advisory Board.
Pre-clinical and regulatory planning for prospective clinical trials (Phase III)
June 20, 2020
Phase I Engineering begins.
June 18, 2020
PressurePace™ bench-top engineering phase formally commences with Medtronic.
Third retrospective clinical trial
Sapienza Medical School, Rome, reviews data on 176 patients with DRH, HFpEF, and implanted pacemakers followed for up to six years.
Scientific Advisory Board is formed.
World-renowned cardiac electrophysiologist, Dr. Kenneth Ellenbogen FACC FHRS, becomes Chairman of the Scientific Advisory Board.
Filings of first two patents.
Three more have been filed since for a total of five patents, including application for international protection.
At the Cardiovascular Medical Group of Southern California in Los Angeles, Eli Gang MD studies 32 patients with DRH and HFpEF, one year pre- and one year post-pacemaker implant.
Michael Burnam MD conducts geriatric group study in Los Angeles,
30 patients with DRH and HFpEF, one year pre- and one year post-pacemaker implant.
BaroPace LLC is incorporated in the State of Delaware.
Changed to C Corp, BaroPace, Inc. in December 2020
Initial observations by Michael Burnam MD lead to his theory that BP can be regulated by pacing the heart.
2014 – 2018